InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer

JENA, Germany, Sept. 17, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced two management appointments. Effective October 1, 2020, Thomas Taapken, Ph.D. will join InflaRx as Chief Financial Officer. Jordan Zwick has been promoted to Chief Strategy Office